Skip to content

Zevra Therapeutics, Inc. ZVRA Gain (loss) on extinguishment of debt

Gain (loss) on extinguishment of debt at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0+100%
TG Therapeutics logo
TG TherapeuticsTGTX

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s gain (loss) on extinguishment of debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s gain (loss) on extinguishment of debt?
Zevra Therapeutics, Inc. (ZVRA) reported gain (loss) on extinguishment of debt of -$2.76M in Q1 2026.
What does gain (loss) on extinguishment of debt mean?
Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.